EMEA-000625-PIP01-09-M03
Key facts
Invented name |
Olysio
|
Active substance |
simeprevir
|
Therapeutic area |
Infectious diseases
|
Decision number |
P/0325/2018
|
PIP number |
EMEA-000625-PIP01-09-M03
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of chronic viral hepatitis C
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Janssen-Cilag International NV
Tel. +32 1460 2111 E-mail: contact@janssen-emea.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|